128 related articles for article (PubMed ID: 2806423)
1. Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence.
Harnois C; Marcotte G; Di Paolo T
Exp Eye Res; 1989 Oct; 49(4):543-52. PubMed ID: 2806423
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice.
Mitsumoto Y; Watanabe A; Mori A; Koga N
Biochem Biophys Res Commun; 1998 Jul; 248(3):660-3. PubMed ID: 9703982
[TBL] [Abstract][Full Text] [Related]
3. Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates.
Ghilardi MF; Chung E; Bodis-Wollner I; Dvorzniak M; Glover A; Onofrj M
Life Sci; 1988; 43(3):255-62. PubMed ID: 3260986
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
Fuxe K; Janson AM; Rosén L; Finnman UB; Tanganelli S; Morari M; Goldstein M; Agnati LF
Exp Brain Res; 1992; 88(1):117-30. PubMed ID: 1347270
[TBL] [Abstract][Full Text] [Related]
5. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Battaglia G; Busceti CL; Molinaro G; Biagioni F; Storto M; Fornai F; Nicoletti F; Bruno V
J Neurosci; 2004 Jan; 24(4):828-35. PubMed ID: 14749427
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and toxicity toward nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues.
Fries DS; de Vries J; Hazelhoff B; Horn AS
J Med Chem; 1986 Mar; 29(3):424-7. PubMed ID: 3485197
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of acute and chronic haloperidol administration on dopamine turnover in rat nigrostriatal and retinal dopaminergic neurons.
Melamed E; Durst R; Frucht Y; Globus M
Eur J Pharmacol; 1983 May; 89(3-4):279-82. PubMed ID: 6873163
[TBL] [Abstract][Full Text] [Related]
8. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
[TBL] [Abstract][Full Text] [Related]
9. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse.
Ferraro TN; Golden GT; DeMattei M; Hare TA; Fariello RG
Neuropharmacology; 1986 Sep; 25(9):1071-4. PubMed ID: 2430229
[TBL] [Abstract][Full Text] [Related]
10. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Przedborski S; Jackson-Lewis V; Yokoyama R; Shibata T; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 1996 May; 93(10):4565-71. PubMed ID: 8643444
[TBL] [Abstract][Full Text] [Related]
11. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
Gerhardt GA; Cass WA; Huettl P; Brock S; Zhang Z; Gash DM
Brain Res; 1999 Jan; 817(1-2):163-71. PubMed ID: 9889359
[TBL] [Abstract][Full Text] [Related]
12. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse.
Perry TL; Yong VW; Jones K; Wall RA; Clavier RM; Foulks JG; Wright JM
Neurosci Lett; 1985 Aug; 58(3):321-6. PubMed ID: 3876525
[TBL] [Abstract][Full Text] [Related]
13. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Pérez-Otaño I; Oset C; Luquin MR; Herrero MT; Obeso JA; Del Río J
Neurosci Lett; 1994 Jul; 175(1-2):121-5. PubMed ID: 7970192
[TBL] [Abstract][Full Text] [Related]
14. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.
Callier S; Morissette M; Grandbois M; Di Paolo T
Synapse; 2000 Sep; 37(4):245-51. PubMed ID: 10891861
[TBL] [Abstract][Full Text] [Related]
15. Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease.
Hilario WF; Herlinger AL; Areal LB; de Moraes LS; Ferreira TA; Andrade TE; Martins-Silva C; Pires RG
J Mol Neurosci; 2016 Dec; 60(4):453-464. PubMed ID: 27660217
[TBL] [Abstract][Full Text] [Related]
16. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Rai SN; Yadav SK; Singh D; Singh SP
J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
[TBL] [Abstract][Full Text] [Related]
17. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
[TBL] [Abstract][Full Text] [Related]
18. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum.
Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH
Life Sci; 1987 Jan; 40(2):193-202. PubMed ID: 3491946
[TBL] [Abstract][Full Text] [Related]
19. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
20. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.
Sonsalla PK; Heikkila RE
Eur J Pharmacol; 1986 Oct; 129(3):339-45. PubMed ID: 3490988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
